ESMO 2017: Kidney Cancer Poster Discussion – Invited Discussant

Madrid, Spain (UroToday.com) Dr. Camillo Porta from Pavia, Italy provided an exceptional discussant presentation of four high-level renal cell carcinoma posters at today’s ESMO 2017 poster discussion symposium. The four posters discussed included “Progression-free survival by independent review and updated overall survival results from Alliance A031203 trial (CABOSUN): cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma” [1] by Dr. Toni Choueiri and colleagues, “IMmotion150: Novel Radiological Endpoints and Updated Data From a Randomized Phase II Trial Investigating Atezolizumab With or Without Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma” [2] by Dr. Thomas Powles and colleagues, “Pazopanib or Sorafenib + Radium-223 in Metastatic Renal Cell Carcinoma with Bone Metastases” [3] by Dr. Dominick Bosse and colleagues, and “Adjuvant sunitinib in patients with high risk renal cell carcinoma (RCC): Safety and therapy management in S-TRAC trial” [4] by Dr. Michael Staehler and colleagues.

ESMO 2017: Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma: Real world data from an Italian Expanded Access Program

Madrid, Spain (UroToday.com)At ESMO 2017 in Madrid Spain, Dr. Procopio and colleagues from Italy presented data from the Italian Expanded Access Program (EAP) for using cabozantinib for metastatic renal cell carcinoma (mRCC). The results of the randomized phase III METEOR trial confirmed a survival benefit of cabozantinib over everolimus in patients with advanced clear-cell renal cell carcinoma who progressed after at least one previous antiangiogenic inhibitor [1]. The objective of the current study was to assess results from the Italian EAP for the treatment of mRCC with cabozantinib in real world clinical practice.

ESMO 2017: SPAZO2 (SOGUG): Validation of the International Metastatic Database Consortium prognostic classification for targeted therapies as 2nd-line after 1st-line pazopanib in metastatic renal cell carcinoma

Madrid, Spain (UroToday.com) Dr. Pérez-Valderrama and Spanish colleagues presented their results of the IMDC validation for targeted therapies as second-line after first-line pazopanib in patients with metastatic renal cell carcinoma (mRCC) at the ESMO 2017 poster session. Only 2% of patients included in the IMDC prognostic model for second-line targeted agents for mRCC had received first-line pazopanib [1]. The objective of this study was to validate the IMDC model for this population of patients receiving first-line pazopanib.

ESMO 2017: Outcomes of patients with metastatic renal cell carcinoma who were treated with second-line vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI) after first-line immune checkpoint inhibitor therapy

Madrid, Spain (UroToday.com) Dr. Shah and colleagues from the MD Anderson Cancer Center presented their results of metastatic renal cell carcinoma (mRCC) patients receiving VEGFR-TKI therapy after first-line immune checkpoint inhibitor therapy at today’s poster session at ESMO 2017. Immune checkpoint inhibitor therapy is an established strategy in mRCC after progressive disease on VEGFR-TKI, however little data exists in the reverse sequence on response rate, progression-free survival (PFS), safety, and tolerability of TKI after first-line immune checkpoint inhibitor therapy.

ESMO 2017: Association between biopsychosocial distress and overall survival in patients with metastatic renal cell carcinoma

Madrid, Spain (UroToday.com) Dr. Bergerot and colleagues presented their study assessing biopsychosocial distress and overall survival (OS) among patients with metastatic renal cell carcinoma (mRCC). Previous studies have found that depressive symptoms are associated with poorer OS in patients with mRCC [1]. In other malignancies, biopsychosocial distress has also been linked to poorer OS, but in mRCC, this association is unclear. The objective of this study was to perform a single institutional assessment of rates and types of distress and evaluating the association between distress and OS.

ESMO 2017: SPAZO2 (SOGUG): Comparative effectiveness of everolimus vs axitinib as second-line after first-line pazopanib in metastatic renal carcinoma

Madrid, Spain (UroToday.com) Dr. Jose Angel Arranz Arija and Spanish colleagues presented their results of everolimus vs axitinib as second-line therapy after first-line pazopanib for patients with metastatic renal cell carcinoma (mRCC) at today’s poster session at ESMO 2017. Pivotal studies assessing axitinib [1] and everolimus [2] in the second-line for mRCC did not include patients treated with first-line pazopanib. In addition, everolimus vs axitinib have not been directly compared in clinical trials in this setting. The authors aimed to compare the effectiveness of everolimus vs axitinib in real world clinical practice, as second-line after pazopanib in mRCC.

ESMO 2017: Cabozantinib for the treatment of patients with metastatic variant histology renal cell carcinoma: A retrospective study

Madrid, Spain (UroToday.com) Dr. Matthew Campbell and colleagues from MD Anderson Cancer Center presented their experience with using cabozantinib in patients with metastatic variant histology renal cell carcinoma (RCC) at today’s ESMO 2017 meeting in Madrid, Spain. Based on phase III study results, it is established that cabozantinib prolongs overall survival (OS) and progression-free survival (PFS) in patients with metastatic clear-cell RCC that progressed on first-line VEGFR-TKIs [1].
Page 1 of 3